Treatment of brain damage

• US 6,569,421 B2
• Filed: 03/29/2000
• Issued: 05/27/2003
• Est. Priority Date: 03/29/1999
• Status: Expired due to Term

• Current Assignee: ReNeuron Limited (ReNeuron Group Plc)
• Original Assignee: ReNeuron Limited (ReNeuron Group Plc)
• Inventors: Hodges, Helen
• Primary Examiner(s): Kunz; Gary
• Assistant Examiner(s): Gucker; Stephen
• Application Number:
  US09/537,617
• Publication Number:
  US 20020037277A1
• Time in Patent Office: 1,154 Days
• Field of Search: 424/93.7,93.2,93.21 128/732 435/240.2,240.1,325,354,352 434/362
• US Class Current: 424/93.2
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36

Abstract

The present invention relates to the treatment of brain damage by cellular transplantation. According to one aspect of the invention, a method for treating a motor, sensory and/or cognitive deficit comprises administering a composition comprising pluripotent cells into the damaged brain in a region contra-lateral to that containing the site of damage. The cells are preferably conditionally immortal.

Claims

1. A method for treating a cognitive deficit in a mammal caused by brain damage, said method comprising administering pluripotent cells into a damaged mammalian brain, wherein said damage is primarily in one hemisphere and said administration is into the brain hemisphere contra-lateral to the brain hemisphere containing the primary site of damage, wherein said pluripotent cells are hippocampal mouse cells comprising a gene encoding the tsA58 mutant of the SV40 large T antigen under the control of an H-2K^b promoter, wherein said pluripotent cells are capable of differentiating into neural cells, and wherein said pluripotent cells are administered in an amount effective to improve cognitive function.

2. The method, according to claim 1, wherein brain damage is associated with stroke.

3. The method, according to claim 1, wherein said pluripotent cells are neuroepithelial stem cells.

4. The method, according to claim 1, wherein said pluripotent cells are from the MHP36 clonal cell line.

5. The method, according to claim 1, wherein the brain is stimulated by exercise after administering the pluripotent cells.

6. The method, according to claim 5, wherein said exercise is augmented by bio-feedback.

7. The method, according to claim 1, wherein said pluripotent cells are administered only into the brain hemisphere contra-lateral to the brain hemisphere containing the primary site of damage.

8. The method, according to claim 1, wherein said pluripotent cells are administered at multiple sites into the brain hemisphere contra-lateral to the brain hemisphere containing the primary site of damage.

9. The method, according to claim 1, wherein said pluripotent cells are administered into an undamaged area of the brain.

10. The method, according to claim 1, wherein said pluripotent cells are administered intraparenchymally.

11. The method, according to claim 1, wherein said pluripotent cells are administered intraparenchymally into an undamaged area of the brain.

12. The method, according to claim 7, wherein said pluripotent cells are administered into an undamaged area of the brain.

13. The method, according to claim 7, wherein said pluripotent cells are administered intraparenchymally.

14. The method, according to claim 7, wherein said pluripotent cells are administered intraparenchymally into an undamaged area of the brain.

15. The method, according to claim 1, wherein said pluripotent cells are derived from an H-2K^b-tsA58 transgenic mouse.